PTC and Sysmex America announced on Tuesday that Sysmex has expanded its use of the ThingWorx Industrial Innovation Platform to enable Sysmex to revolutionize the delivery of blood test results with the Sysmex XW-100 automated hematology CBC analyzer.
The pursuit of IoT innovation led Sysmex to adopt ThingWorx. The Industrial Innovation Platform enabled Sysmex to expand the availability of product data and implement transformative connected solutions that were previously beyond reach.
Prior to the XW-100, virtually all hematology analyzers required skilled clinical personnel to perform blood sample analysis and validate results. This innovation enables blood tests to be safely performed by a broader range of practitioners, improving access to and speed of care.
The XW-100 is an automated hematology analyzer developed for CLIA-waived use. Instead of sending blood samples to outside laboratories and awaiting the results, the XW-100 makes it possible for one of the most frequently requested blood tests, the CBC, to be performed in medical offices where patients are first treated. On-site blood test results are available to patients in as few as three minutes.
“The Sysmex Innovation team continues to deliver exceptional value by leveraging the ThingWorx Industrial Innovation Platform,” said Ralph Taylor, chief executive officer, Sysmex America. “The combination of the ThingWorx Industrial Innovation Platform with the XW-100 enables Sysmex to revolutionize the delivery of common blood test results by reducing time to diagnosis, enabling faster treatment plans, and improving the efficiency of health care delivery.”
“Sysmex has embraced continual innovation as an integral part of its core business model,” said Jim Heppelmann, president and CEO, PTC. “Leveraging ThingWorx enables Sysmex America to continue to deliver high-value IoT-enabled solutions to its customers and help retain its leadership position in an intensely competitive market. We congratulate Sysmex on this breakthrough technology.”
